IS4871A - Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF) - Google Patents

Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)

Info

Publication number: IS4871A
Authority: IS; Iceland
Prior art keywords: pde; phosphodiesterase; tnf; inhibitors; established
Prior art date: 1996-05-03

Application number

IS4871A

Other languages

English (en)

Inventor

Marfat Anthony

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-03

Filing date

1998-10-16

Publication date

1998-10-16

1998-10-16 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

1998-10-16 Publication of IS4871A publication Critical patent/IS4871A/is

Links

102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 2
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 2
108060008682 Tumor Necrosis Factor Proteins 0.000 title 2
102000003390 tumor necrosis factor Human genes 0.000 title 2
125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Hematology (AREA)
Oncology (AREA)
Transplantation (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IS4871A 1996-05-03 1998-10-16 Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF) IS4871A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1686196P	1996-05-03	1996-05-03
PCT/IB1997/000323 WO1997042174A1 (en)	1996-05-03	1997-04-01	Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (1)

Publication Number	Publication Date
IS4871A true IS4871A (is)	1998-10-16

Family

ID=21779401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4871A IS4871A (is)	1996-05-03	1998-10-16	Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)

Country Status (41)

Country	Link
US (2)	US6211222B1 (is)
EP (1)	EP0912521B1 (is)
JP (1)	JP3148254B2 (is)
KR (1)	KR100339935B1 (is)
CN (2)	CN1112359C (is)
AP (4)	AP2001002304A0 (is)
AR (1)	AR006906A1 (is)
AT (1)	ATE292626T1 (is)
AU (1)	AU725576B2 (is)
BG (1)	BG64211B1 (is)
BR (1)	BR9709051A (is)
CA (2)	CA2252982C (is)
CO (1)	CO4650038A1 (is)
CZ (1)	CZ292825B6 (is)
DE (1)	DE69732966T2 (is)
DZ (1)	DZ2217A1 (is)
EA (1)	EA002272B1 (is)
ES (1)	ES2238079T3 (is)
GT (1)	GT199700043A (is)
HN (1)	HN1997000046A (is)
HR (1)	HRP970227B1 (is)
HU (1)	HUP9902459A3 (is)
ID (1)	ID16856A (is)
IL (2)	IL152083A0 (is)
IS (1)	IS4871A (is)
MA (1)	MA24158A1 (is)
MY (1)	MY132499A (is)
NO (1)	NO312959B1 (is)
NZ (1)	NZ332240A (is)
OA (1)	OA10904A (is)
PE (1)	PE64598A1 (is)
PL (1)	PL329836A1 (is)
SK (1)	SK148298A3 (is)
TN (1)	TNSN97070A1 (is)
TR (1)	TR199802202T2 (is)
TW (1)	TW449585B (is)
UA (1)	UA65536C2 (is)
UY (1)	UY24532A1 (is)
WO (1)	WO1997042174A1 (is)
YU (1)	YU16397A (is)
ZA (1)	ZA973804B (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP2001002304A0 (en) *	1996-05-03	2001-12-31	Pfizer	Substituted indazole derivatives and related compounds
US6005118A (en) *	1996-05-03	1999-12-21	Caron; Stephane	Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
CA2258728C (en)	1996-06-19	2011-09-27	Rhone Poulenc Rorer Limited	Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
ES2172882T3 (es) *	1997-05-08	2002-10-01	Pfizer Prod Inc	Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos.
TR200001234T2 (tr) *	1997-11-04	2000-08-21	Pfizer Products Inc.	Terapötik aktif bileşiklerde katelkolün indazol biyoisoster değişimi.
IL126745A (en) *	1997-11-04	2003-09-17	Pfizer Prod Inc	Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
CN1281441A (zh) *	1997-11-04	2001-01-24	辉瑞产品公司	以在pde4抑制剂中的儿茶酚的吲唑生物等排物置换为基础的治疗活性化合物
IL132407A0 (en) *	1998-10-21	2001-03-19	Pfizer Prod Inc	Method for treating congestive heart failure
JP2000198734A (ja) *	1998-12-30	2000-07-18	Pfizer Inc	胃運動性減弱および関連疾患の治療のための運動性増強薬
US6303782B1 (en) *	1999-04-20	2001-10-16	Pfizer Inc	Process for preparing benzylnitriles
US6362213B1 (en)	1999-12-23	2002-03-26	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
DE60018470T2 (de) *	1999-12-23	2006-02-16	Icos Corp., Bothell	Cyclische amp spezifische phosphodiesterase inhibitoren
US7211594B2 (en) *	2000-07-31	2007-05-01	Signal Pharmaceuticals, Llc	Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) *	2000-07-31	2005-05-24	Signal Pharmaceuticals, Inc.	Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US6953774B2 (en)	2000-08-11	2005-10-11	Applied Research Systems Ars Holding N.V.	Methods of inducing ovulation
PT1908463E (pt)	2001-12-14	2011-12-19	Merck Serono Sa	Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
US20040034084A1 (en) *	2002-05-24	2004-02-19	Celgene Corporation	Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) *	2002-11-08	2007-03-27	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) *	2002-12-31	2005-01-27	Zeldis Jerome B.	Drug-coated stents and methods of use therefor
DE10318610A1 (de)	2003-04-24	2004-11-11	Elbion Ag	7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en)	2004-10-26	2009-10-13	Wyeth	Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) *	2005-03-23	2007-01-04	Bhagwat Shripad S	Methods for treating or preventing acute myelogenous leukemia
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (en)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021016B1 (en) *	2006-04-21	2016-01-06	Janssen Biotech, Inc.	Cxcl-13 antagonists and tnf-alpha antagonists for use in a combination therapy
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use
AU2018360766B2 (en)	2017-11-06	2024-09-19	Rapt Therapeutics, Inc.	Anticancer agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3994890A (en) *	1974-01-31	1976-11-30	Chugai Seiyaku Kabushiki Kaisha	1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) *	1979-10-09	1981-05-14	Konishiroku Photo Ind Co Ltd	Direct positive image forming method
GB8707051D0 (en) *	1986-04-15	1987-04-29	Ici America Inc	Heterocyclic carboxamides
JP2525286B2 (ja) *	1990-11-26	1996-08-14	日本原子力研究所	超耐熱性炭化ケイ素繊維の製造方法
TW223004B (is) *	1991-11-25	1994-05-01	Sumitomo Chemical Co
US5444038A (en) *	1992-03-09	1995-08-22	Zeneca Limited	Arylindazoles and their use as herbicides
HU217661B (hu) *	1992-03-09	2000-03-28	Zeneca Ltd.	Aril-indazol-származékok, eljárás az előállításukra és herbicidként történő alkalmazásuk
FI944549L (fi) *	1992-04-02	1994-11-30	Smithkline Beecham Corp	Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
US5554620A (en) *	1993-09-14	1996-09-10	Sterling Winthrop Inc.	Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) *	1993-12-07	1995-08-08	Miles Inc.	Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
PL319758A1 (en) *	1994-10-20	1997-08-18	Pfizer	Bicyclic tetrahydropyrasole pyridines and their application as medicines
KR970707243A (ko) *	1994-10-21	1997-12-01	헤이만, 로버트 엘	금속제품에 대한 내식성 완충 시스템(corrosion resistant buffer system for metal products)
AP2001002304A0 (en) *	1996-05-03	2001-12-31	Pfizer	Substituted indazole derivatives and related compounds
ES2172882T3 (es) *	1997-05-08	2002-10-01	Pfizer Prod Inc	Procedimientos y productos intermedios para la preparacion de derivados indazol sustituidos.

1996
- 1996-05-03 AP AP2001002304A patent/AP2001002304A0/xx unknown
- 1996-05-03 AP APAP/P/2001/002294A patent/AP1147A/en active
1997
- 1997-01-04 UA UA98105434A patent/UA65536C2/uk unknown
- 1997-04-01 EA EA199800882A patent/EA002272B1/ru not_active IP Right Cessation
- 1997-04-01 BR BR9709051A patent/BR9709051A/pt active Search and Examination
- 1997-04-01 NZ NZ332240A patent/NZ332240A/xx unknown
- 1997-04-01 CN CN97194356A patent/CN1112359C/zh not_active Expired - Fee Related
- 1997-04-01 WO PCT/IB1997/000323 patent/WO1997042174A1/en not_active Ceased
- 1997-04-01 CA CA002252982A patent/CA2252982C/en not_active Expired - Fee Related
- 1997-04-01 EP EP97907247A patent/EP0912521B1/en not_active Expired - Lifetime
- 1997-04-01 IL IL15208397A patent/IL152083A0/xx unknown
- 1997-04-01 SK SK1482-98A patent/SK148298A3/sk unknown
- 1997-04-01 KR KR1019980708867A patent/KR100339935B1/ko not_active Expired - Fee Related
- 1997-04-01 TW TW086104176A patent/TW449585B/zh active
- 1997-04-01 CZ CZ19983492A patent/CZ292825B6/cs not_active IP Right Cessation
- 1997-04-01 PL PL97329836A patent/PL329836A1/xx unknown
- 1997-04-01 JP JP53967097A patent/JP3148254B2/ja not_active Expired - Fee Related
- 1997-04-01 IL IL12654797A patent/IL126547A/xx not_active IP Right Cessation
- 1997-04-01 DE DE69732966T patent/DE69732966T2/de not_active Expired - Fee Related
- 1997-04-01 AU AU19373/97A patent/AU725576B2/en not_active Ceased
- 1997-04-01 TR TR1998/02202T patent/TR199802202T2/xx unknown
- 1997-04-01 HU HU9902459A patent/HUP9902459A3/hu unknown
- 1997-04-01 ES ES97907247T patent/ES2238079T3/es not_active Expired - Lifetime
- 1997-04-01 AT AT97907247T patent/ATE292626T1/de not_active IP Right Cessation
- 1997-04-01 CA CA002389918A patent/CA2389918A1/en not_active Abandoned
- 1997-04-01 AP APAP/P/2001/002304A patent/AP0102304A0/en unknown
- 1997-04-04 HN HN1997000046A patent/HN1997000046A/es unknown
- 1997-04-10 GT GT199700043A patent/GT199700043A/es unknown
- 1997-04-28 UY UY24532A patent/UY24532A1/es not_active IP Right Cessation
- 1997-04-29 AR ARP970101769A patent/AR006906A1/es not_active Application Discontinuation
- 1997-04-29 YU YU16397A patent/YU16397A/sh unknown
- 1997-04-30 AP APAP/P/1997/000975A patent/AP1146A/en active
- 1997-04-30 DZ DZ970064A patent/DZ2217A1/fr active
- 1997-04-30 MA MA24577A patent/MA24158A1/fr unknown
- 1997-04-30 TN TNTNSN97070A patent/TNSN97070A1/fr unknown
- 1997-04-30 PE PE1997000330A patent/PE64598A1/es not_active Application Discontinuation
- 1997-05-02 ID IDP971466A patent/ID16856A/id unknown
- 1997-05-02 MY MYPI97001923A patent/MY132499A/en unknown
- 1997-05-02 ZA ZA973804A patent/ZA973804B/xx unknown
- 1997-05-02 HR HR970227A patent/HRP970227B1/xx not_active IP Right Cessation
- 1997-05-05 CO CO97023872A patent/CO4650038A1/es unknown
- 1997-11-04 US US08/963,904 patent/US6211222B1/en not_active Expired - Fee Related
1998
- 1998-10-16 IS IS4871A patent/IS4871A/is unknown
- 1998-10-23 OA OA9800201A patent/OA10904A/en unknown
- 1998-11-02 NO NO19985095A patent/NO312959B1/no not_active IP Right Cessation
- 1998-11-23 BG BG102946A patent/BG64211B1/bg unknown
1999
- 1999-09-27 US US09/406,220 patent/US6127398A/en not_active Expired - Fee Related
2002
- 2002-11-08 CN CN02149950A patent/CN1422849A/zh active Pending

Also Published As

Publication number	Publication date
US6127398A (en)	2000-10-03
PL329836A1 (en)	1999-04-12
JPH11508284A (ja)	1999-07-21
MY132499A (en)	2007-10-31
HUP9902459A2 (hu)	1999-11-29
CA2389918A1 (en)	1997-11-13
JP3148254B2 (ja)	2001-03-19
CO4650038A1 (es)	1998-09-03
AP2001002304A0 (en)	2001-12-31
CN1112359C (zh)	2003-06-25
HK1019443A1 (en)	2000-02-11
AR006906A1 (es)	1999-09-29
CZ292825B6 (cs)	2003-12-17
OA10904A (en)	2001-10-11
GT199700043A (es)	1998-10-02
TW449585B (en)	2001-08-11
NO985095L (no)	1998-12-29
BR9709051A (pt)	1999-08-03
AU1937397A (en)	1997-11-26
HRP970227A2 (en)	2000-12-31
ID16856A (id)	1997-11-13
KR20000010751A (ko)	2000-02-25
ATE292626T1 (de)	2005-04-15
NZ332240A (en)	2000-07-28
NO312959B1 (no)	2002-07-22
KR100339935B1 (ko)	2002-07-18
AP9700975A0 (en)	1997-07-31
EP0912521B1 (en)	2005-04-06
AP0102304A0 (en)	1997-11-03
AP1147A (en)	2003-02-25
UY24532A1 (es)	2000-09-29
DE69732966T2 (de)	2005-09-08
AU725576B2 (en)	2000-10-12
AP1146A (en)	2003-02-25
HN1997000046A (es)	1997-06-26
NO985095D0 (no)	1998-11-02
DE69732966D1 (de)	2005-05-12
CA2252982C (en)	2002-10-08
HUP9902459A3 (en)	2001-10-29
PE64598A1 (es)	1998-10-26
EA199800882A1 (ru)	1999-06-24
YU16397A (sh)	1999-12-27
BG102946A (en)	1999-11-30
CZ349298A3 (cs)	1999-09-15
EP0912521A1 (en)	1999-05-06
AP2001002294A0 (en)	2001-12-31
WO1997042174A1 (en)	1997-11-13
UA65536C2 (en)	2004-04-15
IL152083A0 (en)	2003-05-29
CN1217714A (zh)	1999-05-26
SK148298A3 (en)	2000-02-14
TR199802202T2 (xx)	1999-02-22
TNSN97070A1 (fr)	2005-03-15
IL126547A (en)	2003-03-12
CA2252982A1 (en)	1997-11-13
MA24158A1 (fr)	1997-12-31
HRP970227B1 (en)	2002-06-30
CN1422849A (zh)	2003-06-11
BG64211B1 (bg)	2004-05-31
ES2238079T3 (es)	2005-08-16
EA002272B1 (ru)	2002-02-28
DZ2217A1 (fr)	2002-12-03
ZA973804B (en)	1998-11-02
IL126547A0 (en)	1999-08-17
US6211222B1 (en)	2001-04-03

Publication	Publication Date	Title
IS4979A (is)	1999-02-16	Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)
IS4910A (is)	1998-11-27	Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata
NO985095D0 (no)	1998-11-02	Substituerte indazolderivater og deres anvendelse som inhibitorer fosfodiesterase (PDE) type IV og produksjon av tumornekrosefaktor (TNF)
AU2002226911A1 (en)	2002-06-03	Indol derivative and their use as inhibitors of p38 kinase
AU7726898A (en)	1998-12-11	Pyrazole derivatives as p38 kinase inhibitors
AU2396897A (en)	1997-11-12	5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
SI1475377T1 (sl)	2006-12-31	Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
AU5704594A (en)	1994-07-19	Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
AU2002362895A1 (en)	2003-04-28	5-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
HUP0102113A3 (en)	2003-03-28	2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
AU3387999A (en)	1999-10-25	Pyrazole inhibitors of cytokine production
EP0987263A3 (en)	2003-10-15	Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
AU2002346929A1 (en)	2003-04-28	5-acylamino-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
NO20015062D0 (no)	2001-10-18	Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
AU2955195A (en)	1996-02-09	Tumor necrosis factor receptor-ii-associated protein kinase and methods for its use
AU4501199A (en)	1999-12-20	8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
MXPA02009550A (es)	2004-05-14	Derivados de pirano (2,3,c)imidazo(1,2-a]piridina para el tratamiento de trastornos gastrointestinales.
AU2876000A (en)	2000-08-29	Tyrosine kinase inhibitors and methods of using the same
GB0102712D0 (en)	2001-03-21	Cytokine Producion and Tyrosine Kinase Inhibitors
GB0511267D0 (en)	2005-07-13	Indol derivatives and their use as kinase inhibitors
HK1045839A (en)	2002-12-13	Indole-type derivatives as inhibitors of p38 kinase
HK1037179A (en)	2002-02-01	Pyrazole inhibitors of cytokine production